Table 3.

Group comparisons (≥10 MET h/wk increment in MVPA) and changes in clinical outcomes

	SUS-PA (n=27)	UNSUS-PA (n=68)	LO-PA (n=75)	p-value (group)‡	p-value (pairwise) ↑ SUS-PA vs. UNSUS-PA, SUS-PA vs. LO-PA, UNSUS-PA vs. LO-PA
Primary Outcome
FIQ-PI†	3.1 (0.4)	2.1 (0.3)	0.6 (0.3)	<0.01	0.15, <0.01, <0.01
Secondary Outcomes
FIQ-Total	21.2 (3.7)	17.3 (2.3)	8.6 (2.2)	<0.01	0.64, <0.05, <0.05
BPI pain†	2.0 (0.4)	1.4 (0.2)	0.9 (0.2)	<0.05	0.36, <0.05, 0.27
PHQ-8†	4.3 (1.1)	3.1 (0.7)	1.7 (0.7)	0.09	0.66, 0.11, 0.28

^†Values represent adjusted mean changes (standard error) from baseline to week 36, with positive values indicating improvement.

^‡P-values were from multiple linear regression analyses and were adjusted for treatment group assignment, response variable value at study entry, baseline level of MVPA, and use of antidepressants.

^↑Pairwise p-values were from Tukey adjusted multiple comparisons, to control for inflated type I error.

Abbreviations: SUS-PA, ≥10 MET h/wk increment in moderate-vigorous physical activity (MVPA)/wk and sustained; UNSUS-PA, ≥10 MET h/wk increment in MVPA, followed by decline; LO-PA, did not achieve ≥10 MET h/wk increment in MVPA; FIQ-PI, Fibromyalgia Impact Questionnaire-Physical Impairment; BPI, Brief Pain Inventory; PHQ-8, Patient Health Questionnaire-8.